AMG-208 is a highly selective dual inhibitor of c-Met and RON tyrosine kinases, with an IC50 of 9 nM against c-Met; it inhibits HGF-mediated c-Met phosphorylation in PC3 cells (IC50 = 46 nM) and is under investigation in Phase 1 clinical trials for the treatment of cancers driven by c-Met and/or RON signaling pathways.